Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth in 2025.

ABBV stock, with 24% returns since the beginning of 2024, has marginally underperformed the S&P 500 index, up 27%. An ...

ABBV's fourth-quarter earnings and sales beat estimates. Management raises the 2027 forecast for newer immunology drugs to ...

Live Updates Deep Dive into ABBV's Earnings Call 11:53 am Looking through AbbVie’s earnings call, these growth prospects stood out: 1. Skyrizi & Rinvoq Set to Dominate Immunology Market 2025 revenue ...

AbbVie Q4 earnings beat estimates, driven by strong sales of Skyrizi and Rinvoq, with an updated 2027 combined revenue ...

AbbVie ABBV is set to report fourth-quarter and full-year 2024 earnings on Jan. 31, before the opening bell. The Zacks ...

Pfizer has agreed to pay $60 million to resolve allegations brought by the US government that its Biohaven Pharma subsidiary ...

In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...

These drugs have the potential to replace Humira sales. Meanwhile, new migraine drugs, Ubrelvy and Qulipta/Aquipta, represent a combined $3 billion-plus peak sales opportunity. Boosted by its new ...

Other drugs in AbbVie's lineup, including Botox, migraine therapies Qulipta and Ubrelvy, cancer drug Venclexta, and antipsychotic medication Vrayalar, are also delivering strong sales growth.